Benchmark maintained a Buy on OmniAb, Inc. (OABI) on March 06, 2026, after the company released Q4 results. The OABI analyst rating held steady even as the stock moved -1.56% (-$0.03) around the announcement. Stifel also reiterated Buy on March 05, 2026, citing partner growth and commercial momentum. Market capitalization stands at $215,114,268 and the stock trades near $1.81 in recent reports. Meyka AI provides this AI-powered market view and Meyka AI rates OABI with a grade of B. This grade factors S&P 500 comparison, sector performance, growth, metrics, and analyst consensus

OABI analyst rating: Benchmark maintains Buy

Benchmark reaffirmed its Buy rating on March 06, 2026 at 09:20 AM after reviewing OmniAb’s Q4 results. The firm kept its stance despite short-term price movement of -1.56% (-$0.03) reported around the note. Benchmark’s note is summarized in press coverage from StreetInsider with further detail on the firm’s view and timing source.

Other analyst moves and market context for OABI analyst rating

Stifel reiterated Buy two days earlier on March 05, 2026, citing partner growth and corporate updates. That note appears in industry coverage and supports a consensus of positive coverage for OmniAb source. Recent trading shows the stock near $1.81, which gives context to both analyst sentiment and market valuation.

What the maintained Buy means for investors

A maintained Buy signals analyst confidence in OmniAb’s near-term commercial and partnership trajectory. Investors should view the OABI analyst rating as a reaffirmation of growth expectations, not a guarantee of gains. Buyers may consider this as supportive evidence while weighing biotech risk, cash runway, and potential dilution.

Price targets, valuation, and gaps in coverage

The Benchmark note did not publish a public price target in the StreetInsider summary. No new explicit OABI price target appears in the March notes. Investors must rely on market valuation metrics and the reported $215,114,268 market cap and recent trade levels near $1.81 until firms disclose firm targets.

Historical analyst coverage and trend

OmniAb has attracted repeated Buy or reiterated Buy ratings in recent quarters, reflecting steady partner wins and technical progress. The pattern of reiterated Buy ratings suggests analyst conviction, but investors should monitor quarterly updates, partner announcements, and cash burn for confirmation.

Meyka view and the proprietary grade for OABI analyst rating

Meyka AI rates OABI with a grade of B. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. Use this as one input in a broader due diligence process and monitor updates from analysts and company releases. See our OABI page for real-time coverage: Meyka OABI page.

Final Thoughts

Benchmark’s decision to maintain a Buy on OmniAb on March 06, 2026 keeps the OABI analyst rating in positive territory. Multiple firms, including Stifel, have reiterated Buy in early March, which signals continued analyst faith in partner-driven growth and commercialization prospects. Investors should treat these ratings as forward-looking opinions that reflect current public data and analyst models. With a market cap of $215,114,268 and trading near $1.81, the stock remains sensitive to quarterly results, partnership announcements, and financing moves. Watch for any published price targets, upcoming earnings commentary, and cash runway updates. Meyka AI’s grade of B supports a cautious, constructive view. These notes are informational, not investment advice, and investors should combine analyst views with fundamental analysis and risk tolerance before acting

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.